Latest Capital Raise News

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.

The Takeovers Panel has declined to investigate Skin Elements Limited's allegations of undisclosed investor associations following a $2.5 million placement, after 62 Capital agreed to waive transfer restrictions on placement securities.

Bio-Gene Technology has expanded its capital raise to $2.775 million through a share placement priced at 2.5 cents, attaching options exercisable at 3.5 cents pending shareholder approval.

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

Desert Metals Limited has raised $1 million through a placement at a 2.9% premium, backing exploration at its Scotty Lithium and Monger Gold projects alongside new growth opportunities.

Spenda Limited (ASX: SPX) has voluntarily suspended trading of its shares from 2 June 2026 to manage disclosure around its institutional accelerated renounceable entitlement offer (AREO). The suspension is expected to last until 10 June or until the AREO results are announced.

Akora Resources has pushed back the deadline for its $1.7 million entitlement offer to 19 June 2026, responding to shareholder feedback and ensuring broader participation.

Santana Minerals' Bendigo-Ophir Gold Project has entered the hearing phase of its regulatory assessment, with concurrent technical hearings scheduled for June and a statutory decision due by late October 2026.

Godolphin Resources has agreed to sell its 49% interest in the Calarie Project to Adavale Resources in a deal structured around shares and long-dated options, aligning with a strategic shift towards its core assets.

Jindalee Lithium has pushed back the deadline for its A$2.5 million entitlement offer, giving shareholders an extra week to decide on participation. The offer includes attaching options exercisable at A$0.60, aiming to bolster the company’s capital position ahead of key development milestones.

AoFrio Limited has initiated a 1-for-7 renounceable rights offer at NZ$0.07 per share aiming to raise nearly NZ$5 million. This follows a recent $4.56 million placement and supports an aggressive growth strategy targeting $300 million revenue by 2030.

Paradigm Biopharmaceuticals has successfully raised $21.375 million through an oversubscribed Share Purchase Plan and a recent placement, bolstering its balance sheet ahead of key Phase 3 trial milestones.